Anzeige
Mehr »
Login
Montag, 20.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
GOLD-MINEN vor Jahrhundert-Hausse?! Diese Aktie sofort kaufen!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AP4F | ISIN: CA7615161030 | Ticker-Symbol: 31R
Frankfurt
17.05.24
08:01 Uhr
0,010 Euro
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REVIVE THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
REVIVE THERAPEUTICS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,0100,03019.05.

Aktuelle News zur REVIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
23.04.Revive Therapeutics Ltd: Revive receives Bucillamine FDA Type C meeting approval3
23.04.Revive Therapeutics Ltd.: Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID1.225TORONTO, April 23, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
18.04.Revive Therapeutics Ltd: Revive gets FDA acceptance for meeting request3
02.04.Revive Therapeutics Ltd: Revive clinical study enrolls nearly 50% of sample2
02.04.Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder67TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
27.03.Revive Therapeutics Ltd: Revive submits meeting request to U.S. FDA3
27.03.Revive Therapeutics Ltd.: Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID130TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
19.03.Revive Therapeutics Ltd: Revive receives notice to submit Type C meeting request4
19.03.Revive Therapeutics Ltd.: Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID513TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
12.03.Revive Therapeutics Ltd: Revive recaps work on bucillamine, long COVID product3
12.03.Revive Therapeutics Ltd.: Revive Therapeutics Provides Corporate Update376TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
26.02.Revive Therapeutics Ltd: Revive Therapeutics closes $1.18M final tranche2
26.02.Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,1101
01.02.Revive Therapeutics Ltd: Revive proposes phase 2/3 bucillamine clinical study6
01.02.Revive Therapeutics Ltd.: Revive Therapeutics Explores the Use of Bucillamine for Long COVID3
31.01.Revive Therapeutics Ltd: Revive closes $913,500 first tranche of placement3
31.01.Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,5001
25.01.Revive Therapeutics announces offering of up to $3 million2
25.01.Revive Therapeutics Ltd: Revive arranges $3-million private placement4
25.01.Revive Therapeutics Ltd. Announces Offering of Up to $3 Million2
Seite:  Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1